SLC40A1 and nonpapillary renal cell carcinoma: THBS1 has been reported to possess antiangiogenic and antitumor effects [36]; NDUFA4L2 may be the molecular target for ccRCC therapy [37]; SLC40A1 was found to play an inflammatory role in TAMs [38]; it was reported that the KRT8+ state could establish specific intercellular communication with mesenchyme and macrophages during injury repair [39].